A Phase I Study of XJ103 in Chinese Healthy Subjects

Summary

This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 38 healthy subjects based on inclusion and exclusion criteria. Subjects will be assigned to one of four different dosage cohorts. Subjects in each cohort will randomly be given experimental drug or a placebo.

Timeline

Start

2023-09-12

Primary completion

2024-12-24

Completion

2025-03-06

Drugs

Indications